Lisata Therapeutics, Inc. (LSTA)
NASDAQ: LSTA · Real-Time Price · USD
4.580
+0.010 (0.22%)
Jan 28, 2026, 3:30 PM EST - Market open
Lisata Therapeutics Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Lisata Therapeutics stock has a target of 15, which predicts a 227.51% increase from the current stock price of 4.58.
Price Target: $15 (+227.51%)
Analyst Consensus: Buy
* Price targets were last updated on Aug 21, 2025.
Analyst Ratings
The average analyst rating for Lisata Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Brookline Capital | Brookline Capital | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Jan 21, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $15 | Strong Buy | Reiterates | $15 | +227.51% | Aug 21, 2025 |
| Brookline Capital | Brookline Capital | Strong Buy Maintains $20 → $32 | Strong Buy | Maintains | $20 → $32 | +598.69% | Jul 15, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $15 | Strong Buy | Reiterates | $15 | +227.51% | Dec 11, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $15 | Strong Buy | Reiterates | $15 | +227.51% | Nov 21, 2024 |
Financial Forecast
Revenue This Year
71.40K
from 1.00M
Decreased by -92.86%
Revenue Next Year
n/a
from 71.40K
EPS This Year
-2.18
from -2.40
EPS Next Year
-0.98
from -2.18
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 73,500 | n/a | ||||
| Avg | 71,400 | n/a | ||||
| Low | 68,600 | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -92.7% | - | ||||
| Avg | -92.9% | - | ||||
| Low | -93.1% | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | -2.19 | -1.01 | ||
| Avg | -2.18 | -0.98 | ||
| Low | -2.15 | -0.94 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | - | - | ||
| Avg | - | - | ||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.